Expertise in
2
conditions

Karin H. Hansen

Sdr. Boulevard 29, 
Odense, DK 
Expertise in
2
conditions
Sdr. Boulevard 29, 
Odense, DK 

Overview

Karin Hansen practices practicing medicine in Odense, Denmark.

Ms. Hansen is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Metastatic Brain Tumor.

She is actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Sdr. Boulevard 29, Odense, 5000, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
Enrollment Status: Completed
Publish Date: August 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

25 Total Publications

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.
Journal: Future oncology (London, England)
Published: December 18, 2025

Frequently Asked Questions about Karin H. Hansen

Is Karin H. Hansen a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Karin H. Hansen is classified as an Advanced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Karin H. Hansen participate in research or clinical trials?

Yes. Karin H. Hansen has published 25 articles and abstracts on conditions like Lung Cancer. You can view a list of Karin H. Hansen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hansen's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile